Skip to main content
DaehanPharmaceutical logo

DaehanPharmaceutical — Investor Relations & Filings

Ticker · 023910 ISIN · KR7023910003 KO Manufacturing
Open in API
Filings indexed 297 across all filing types
Latest filing 2019-04-30 Major Shareholding Noti…
Country KR South Korea
Listing KO 023910

About DaehanPharmaceutical

https://www.dhnp.co.kr/

Daehan Nupharm is a pharmaceutical company engaged in the research, development, and manufacturing of a diverse portfolio of healthcare products. The company's business is structured around four core areas: human pharmaceuticals, offering a range of therapeutic treatments; animal health products for both companion and livestock animals; advanced bio-pharmaceuticals, with a focus on next-generation technologies like cell therapy; and health functional foods. Established initially in the animal health sector, the company leverages its dedicated Central and Bio Research Institutes to drive innovation and develop solutions for global markets. The R&D efforts concentrate on strengthening technological capabilities and advancing new treatment modalities.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (DART system) used when an entity acquires 5% or more of a company's shares. This falls under the category of Major Shareholding Notification.
2019-04-30 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the shareholding changes of a specific individual (Lee Seung-young, an executive) in the company 'Daehan Pharmaceutical Co., Ltd.' following a market transaction. This type of filing is a standard regulatory requirement for insider trading/shareholding disclosures, which corresponds to the 'Director's Dealing' category.
2019-04-24 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Commission and the Korea Exchange. This type of filing is a mandatory disclosure of insider trading activities, specifically detailing share acquisitions by a company director (Lee Seung-young). According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2019-04-17 Korean
사업보고서 (2018.12)
Audit Report / Information Classification · 1% confidence The document is a comprehensive 'Audit Report' (감사보고서) for Daehan Pharmaceutical Co., Ltd. for the fiscal year ending December 31, 2018. It includes the independent auditor's report, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes to the financial statements. While it contains financial data, it is specifically the formal audit report required by regulatory standards, not a standalone annual report (10-K) or a simple earnings release. Therefore, it is classified as an Audit Report. FY 2018
2019-04-01 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 1% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed by Mirae Asset Global Investments regarding their stake in Daehan Pharmaceutical. This is a standard regulatory filing in South Korea (often referred to as a 5% rule filing) used to notify the market of changes in significant share ownership levels. It details the reporting entity, the issuer, and a chronological list of share transactions. This fits the definition of a 'Major Shareholding Notification'.
2019-04-01 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share transactions (purchases) made by an executive (Lee Seung-young) of Daehan Pharmaceutical Co., Ltd. This type of filing is a standard regulatory requirement for insider trading/director dealings in South Korea, which corresponds to the 'Director's Dealing' category.
2019-03-27 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.